NASDAQ:SLRX Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis $4.37 +0.19 (+4.55%) As of 12:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Salarius Pharmaceuticals Stock (NASDAQ:SLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SLRX alerts:Sign Up Key Stats Today's Range$4.16▼$4.5550-Day Range$3.67▼$8.5452-Week Range$3.64▼$108.00Volume195,502 shsAverage Volume179,467 shsMarket Capitalization$2.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Salarius Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults. Seclidemstat is currently being evaluated in Phase 2 clinical studies, where the company is investigating its efficacy and safety profile in patients with relapsed or refractory disease. In addition to its lead program, Salarius maintains a robust preclinical pipeline of small‐molecule candidates targeting fusion‐driven cancers and other oncology indications. These programs leverage proprietary chemistry platforms to identify novel inhibitors of NEDD8‐activating enzymes and other epigenetic regulators. By addressing oncogenic fusion proteins and key regulatory enzymes that drive tumor growth, Salarius aims to expand its portfolio of precision therapies for patients with unmet medical needs. Founded in 2014 and headquartered in Houston, Texas, Salarius Pharmaceuticals has assembled a management team with extensive experience in oncology drug development, regulatory strategy, and commercialization. The company’s clinical trials are conducted primarily in the United States, with plans to extend development activities into Europe and other regions as part of its global strategy. Salarius also collaborates with academic institutions, patient advocacy groups and research consortia to advance its programs and accelerate the delivery of new cancer therapies to the clinic.AI Generated. May Contain Errors. Read More Salarius Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreSLRX MarketRank™: Salarius Pharmaceuticals scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Salarius Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Salarius Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Salarius Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSalarius Pharmaceuticals has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Salarius Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.65% of the float of Salarius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSalarius Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Salarius Pharmaceuticals has recently decreased by 56.22%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSalarius Pharmaceuticals does not currently pay a dividend.Dividend GrowthSalarius Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.65% of the float of Salarius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSalarius Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Salarius Pharmaceuticals has recently decreased by 56.22%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.97 News SentimentSalarius Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Salarius Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for SLRX on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Salarius Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.88% of the stock of Salarius Pharmaceuticals is held by institutions.Read more about Salarius Pharmaceuticals' insider trading history. Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLRX Stock News HeadlinesSalarius Pharmaceuticals regains compliance with Nasdaq listing rulesOctober 13 at 12:43 PM | msn.comSalarius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Ahead of Merger with Decoy TherapeuticsOctober 13 at 8:50 AM | quiverquant.comQBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff, as the world's biggest car firm prepares to launch a "mind blowing" new product. It has nothing to do with EVs, or self-driving cars. In fact, it's not a car at all...October 15 at 2:00 AM | Altimetry (Ad)Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing RequirementsOctober 13 at 8:45 AM | globenewswire.comSalarius regains compliance with Nasdaq min bid price requirementSeptember 9, 2025 | msn.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 9, 2025 | finanznachrichten.deSalarius Pharmaceuticals Regains Nasdaq Compliance with Minimum Bid Price RequirementSeptember 9, 2025 | quiverquant.comQSalarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 9, 2025 | globenewswire.comSee More Headlines SLRX Stock Analysis - Frequently Asked Questions How have SLRX shares performed this year? Salarius Pharmaceuticals' stock was trading at $27.60 on January 1st, 2025. Since then, SLRX shares have decreased by 84.3% and is now trading at $4.3450. How were Salarius Pharmaceuticals' earnings last quarter? Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($33.00) by $32.55. When did Salarius Pharmaceuticals' stock split? Shares of Salarius Pharmaceuticals reverse split before market open on Tuesday, August 19th 2025.The 1-15 reverse split was announced on Tuesday, August 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Salarius Pharmaceuticals? Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Salarius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/12/2025Today10/15/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLRX Previous SymbolNASDAQ:FLKS CIK1615219 Webwww.salariuspharma.com Phone(832) 834-6992FaxN/AEmployees20Year Founded2011Profitability EPS (Trailing Twelve Months)($43.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-556.47% Return on Assets-192.35% Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.31 per share Price / Book0.29Miscellaneous Outstanding Shares510,000Free Float504,000Market Cap$2.13 million OptionableNot Optionable Beta0.44 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:SLRX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.